Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Amryt Pharma expands route to market for key product

It has inked an exclusive distribution deal with GryNumber Health covering Central and Eastern Europe
men shaking hands
Deal done - the company's new partner has a well established network in the region

Amryt Pharma PLC (LON:AMYT) said it has expanded its route to market its key product Lojuxta.

It has inked an exclusive distribution deal with GryNumber Health covering Central and Eastern Europe, building on similar deals in Saudi Arabia and Switzerland.

READ: Amryt Pharma signs exclusive distributor agreement in Switzerland

"GryNumber Health has a well-established presence in, and significant experience of, the healthcare markets in Central and Eastern Europe and therefore is an ideal partner for us in the region,” said Dr Joe Wiley, Amryt chief executive.

“We are delighted to have signed this exclusive distribution agreement as we look to provide access to Lojuxta to patients suffering from HoFH across our licensed territories."

READ: Amryt Pharma inks exclusive Saudi Arabian distribution agreement for its Lojuxta and AP101 drugs

The company acquired the rights to sell Lojuxta in certain territories just over a year ago. The drug is used to treat a rare and potentially life-threatening genetic disorder called homozygous familial hypercholesterolemia, which is characterised by high LDL cholesterol levels.

View full AMYT profile View Profile

Amryt Pharma PLC Timeline

Related Articles

scientist in lab
August 31 2018
While the data bodes well for MTD201, Midatech is most excited by the validation of its Q-Sphera sustained release technology, which it is using in some of its other compounds
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use